Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: A randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 5, 1998, Pages 367-372

  Naito, Seiji ^a   Kotoh, Shuji ^a   Omoto, Tetsuo ^b   Osada, Yukio ^c   Sagiyama, Kazuyuki ^d   Iguchi, Atsushi ^e   Ariyoshi, Asami ^f   Hiratsuka, Yoshiharu ^g   Kumazawa, Joichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

^d HARASANSHIN HOSPITAL   (Japan)

^e SAGA UNIVERSITY   (Japan)

^f FUKUOKA UNIVERSITY   (Japan)

^g Fukuoka University Chikushi Hospital   (Japan)

Author keywords

Intravesical chemotherapy; Multidrug resistance; Prophylaxis; Superficial bladder cancer

Indexed keywords

DOXORUBICIN; VERAPAMIL;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER IRRITATION; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TRANSURETHRAL RESECTION; TUMOR GROWTH; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VERAPAMIL;

EID: 0031683086     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050831     Document Type: Article

References (17)

1. Akaza H (1997) New strategy of bio-chemoprevention on recurrence of superficial bladder cancer based on a hypothesis of the mechanism of recurrence. Jpn J Cancer Chemother 24 [Suppl. 1]: 253
2. Akaza H, Isaka S, Koiso K, Kotake T, Machida T, Maru A, Matsumura Y, Niijima T, Obata K, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, Uyama T, The Japanese Urological Cancer Research Group for Adriamycin (1987) Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Cancer Chemother Pharmacol 20 [Suppl]: 91
3. Holford TR (1976) Life tables with concomitant information. Biometrics 32: 587
4. Kimiya K, Naito S, Soejima T, Sakamoto N, Kotoh S, Kumazawa J, Tsuruo T (1992) Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ ADM. J Urol 148: 441
5. Lamm DL, Crissman J, Blumenstein B, Crawford ED, Montie J, Scardino P, Grossman HB, Stanisic T, Smith J, Sullivan J, Sarosdy M (1989) Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group study. Progr Clin Biol Res 310: 263
6. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA (1991) A randomized trial of intravesical doxorubicin and immunotherapy with Bacillus Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205
7. Naito S, Sakamoto N, Kotoh S, Goto K, Matsumoto T, Kumazawa J (1992) Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract. Eur Urol 22: 158
8. Naito S, Kimiya K, Ueda T, Kumazawa J, Omoto T, Osada Y, Iguchi A, Ariyoshi A, Sagiyama K (1992) Intravesical therapy with adriamycin plus verapamil in patients with superficial bladder cancer: a pilot study. Urol Int 48: 270
9. Naito S, Ueda T, Kotoh S, Iguchi A, Sagiyama K, Hiratsuka Y, Osada Y, Ariyoshi A, Omoto T, Kumazawa J, The Kyushu University Urological Oncology Group (1994) Prophylactic intravesical chemotherapy with adriamycin plus verapamil for primary superficial bladder cancer: preliminary results. Cancer Chemother Pharmacol 35 [Suppl.]: 76
10. Nakagawa M, Emoto A, Nasu N, Hanadu T, Kuwano M, Cole SPC, Nomura Y (1997) Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 157: 1260
11. Niijima T, Koiso K, Akaza H, The Japanese Urological Cancer Research Group for Adriamycin (1983) Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol 11 [Suppl]: 79
12. Obata K, Ohashi Y, Akaza H, Isaka S, Kagawa S, Koiso K, Kotake T, Machida T, Matsumura Y, Niijima T, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, The Japanese Urological Cancer Research Group for Adriamycin (1994) Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. Cancer Chemother Pharmacol 35 [Suppl]: 88
13. Schulman CC, Denis LJ, Oosterlinck W, De Sy W, Chantrie M, Bouffioux C, Van Cangh PJ, Van Erps P (1983) Early adjuvant adriamycin in superficial bladder carcinoma. World J Urol 1: 86
14. Simpson WG, Tseng MT, Anderson KC, Harty JI (1984) Verapamil enhancement of chemotherapeutic efficacy in human bladder cancer cells. J Urol 132: 574
15. Slater LM, Murray SL, Wetzel MW, Wisdom RM, DuVall EM (1982) Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest 10: 1131
16. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967
17. Ueda T, Naito S, Iguchi A, Sugiyama K, Osada Y, Ariyoshi A, Omoto T, Kumazawa J, The Kyushu University Urological Oncology Group (1992) Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. Cancer Chemother Pharmacol 30 [Suppl]: 31